Lanreotide (Mytolac) 60 mg per 0.5 ml syringe

Supply issue Active

There is a supply issue affecting the 60 mg strength of lanreotide injections (Pharmacode 2698145).

Affected product

The supplier, Boucher & Muir, has run out of the following strength of lanreotide:

  • Presentation: inj 60 mg per 0.5 ml, 0.5 ml syringe
  • Brand: Mytolac
  • Pharmacode: 2698145
  • Subsidy: $382.77
  • Measure / Qty: per 1

The 120 mg (Pharmacode: 2698161) remains available. The 90 mg (Pharmacode: 2698153) has not yet arrived in New Zealand. It is expected to be available in early July 2025.

People who use lanreotide

You may need to talk to the person who prescribed your lanreotide about the right alternative for you. A different brand of lanreotide is available. It contains the same active ingredient in the same amount.

It has not been approved by Medsafe for use in New Zealand, this means your doctor and pharmacist have extra steps they need to follow before giving you the lanreotide.  

Alternative product

The supplier has found an alternative product. It will be listed from 1 July 2025. It will be available in early July 2025. It is not Medsafe approved. Which means it will need to be prescribed and dispensed in line with section 29 of the Medicines Act.

  • Presentation: inj 60 mg per 0.5 ml, 0.5 ml syringe
  • Brand: Mytolac (s29)
  • Pharmacode: 2709597
  • Subsidy: $382.77
  • Measure / Qty: per 1

Flyer for pharmacists

Prescribing and supplying an unapproved medicine

Section 29 of the Medicines Act 1981 allows for medicines that are not Medsafe approved to be prescribed and supplied to people. The medicine must be prescribed by someone registered with the Medical Council of New Zealand – such as, a doctor. 

We know supplying a medicine under section 29 is not ideal. In this case, however, this will allow patients to be able to access an appropriate treatment. 

We apologise for any inconvenience this causes. 

Advice for prescribing under section 29 – BPAC website(external link) 

Prescriber and pharmacist requirements for section 29 medicines – Medsafe website (external link)

Medsafe’s section 29 Declaration / Notification Form [DOC](external link)

What patients need to know about unapproved medicines – Healthify website(external link)

Expected resupply

The supplier expects to have registered stock of the 60 mg Mytolac available again in 2026.

Who to contact

If you have questions about this issue, email enquiry@pharmac.govt.nz

Please include as much information as you can about the product (presentation, brand, pharmacode) and who your wholesaler is.

Sign up to our email list for regular emails about supply issues and more(external link)